Insider Selling: Ocular Therapeutix (NASDAQ:OCUL) Insider Sells 10,348 Shares of Stock

Ocular Therapeutix, Inc. (NASDAQ:OCUL) insider Sanjay Nayak sold 10,348 shares of the stock in a transaction on Thursday, February 12th. The stock was sold at an average price of $9.04, for a total value of $93,545.92. Following the completion of the sale, the insider owned 332,412 shares in the company, valued at approximately $3,005,004.48. The trade was a 3.02% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Ocular Therapeutix Trading Down 21.3%

OCUL stock traded down $1.89 during trading on Tuesday, hitting $6.99. The company had a trading volume of 51,503,167 shares, compared to its average volume of 4,346,415. Ocular Therapeutix, Inc. has a 52-week low of $5.78 and a 52-week high of $16.44. The company has a 50 day simple moving average of $11.22 and a 200-day simple moving average of $11.78. The firm has a market capitalization of $1.52 billion, a P/E ratio of -4.85 and a beta of 0.90. The company has a quick ratio of 15.32, a current ratio of 15.39 and a debt-to-equity ratio of 0.11.

Ocular Therapeutix (NASDAQ:OCUL) last issued its earnings results on Thursday, February 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.04. Ocular Therapeutix had a negative net margin of 511.90% and a negative return on equity of 70.68%. The business had revenue of $13.25 million for the quarter, compared to analyst estimates of $16.13 million. During the same period last year, the company posted ($0.29) earnings per share. The company’s quarterly revenue was down 22.4% compared to the same quarter last year. As a group, research analysts forecast that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Ocular Therapeutix

A number of large investors have recently added to or reduced their stakes in OCUL. Millennium Management LLC lifted its holdings in Ocular Therapeutix by 3,136.1% during the third quarter. Millennium Management LLC now owns 3,855,706 shares of the biopharmaceutical company’s stock valued at $45,073,000 after purchasing an additional 3,736,560 shares in the last quarter. Alliancebernstein L.P. raised its position in shares of Ocular Therapeutix by 2,003.2% during the 3rd quarter. Alliancebernstein L.P. now owns 3,424,439 shares of the biopharmaceutical company’s stock worth $40,032,000 after purchasing an additional 3,261,619 shares during the last quarter. Avoro Capital Advisors LLC raised its position in shares of Ocular Therapeutix by 38.5% during the 3rd quarter. Avoro Capital Advisors LLC now owns 10,250,000 shares of the biopharmaceutical company’s stock worth $119,822,000 after purchasing an additional 2,850,000 shares during the last quarter. Vanguard Group Inc. lifted its stake in Ocular Therapeutix by 26.3% in the 4th quarter. Vanguard Group Inc. now owns 11,575,193 shares of the biopharmaceutical company’s stock valued at $140,523,000 after buying an additional 2,411,953 shares in the last quarter. Finally, Balyasny Asset Management L.P. boosted its holdings in Ocular Therapeutix by 902.9% in the 3rd quarter. Balyasny Asset Management L.P. now owns 2,189,276 shares of the biopharmaceutical company’s stock worth $25,593,000 after buying an additional 1,970,983 shares during the last quarter. 59.21% of the stock is currently owned by institutional investors and hedge funds.

More Ocular Therapeutix News

Here are the key news stories impacting Ocular Therapeutix this week:

• Positive Sentiment: SOL‑1 demonstrated statistical superiority to Regeneron’s Eylea on the trial’s vision endpoint, supporting Ocular’s plan to pursue an FDA filing and a potential new treatment option in wet AMD. Ocular Therapeutix’s eye drug superior to Regeneron’s Eylea in late-stage trial
• Positive Sentiment: Company and coverage note a clear regulatory path — Ocular is talking about an FDA submission based on the Phase 3 win, which could materially change the company’s product mix if approved. Ocular’s Hydrogel Beats Regeneron’s Eylea in Wet AMD Study, Plots Path to FDA
• Neutral Sentiment: Ocular released topline SOL‑1 results and corporate commentary; the data readout itself is positive but investors are parsing subgroup/endpoint details and next steps. Ocular Therapeutix releases positive topline results from SOL-1
• Negative Sentiment: Despite the win, shares fell sharply because the observed benefit was characterized as modest and, crucially, the comparator in some analyses was a lower‑dose/less‑favorable version of Eylea — raising questions about clinical meaningfulness and commercial differentiation. Ocular Therapeutix plunges as modest benefit overshadow trial win over Regeneron’s Eylea
• Negative Sentiment: Market and analyst coverage flagged investor skepticism — headlines note a 25–35% intraday decline on heavy volume as traders focused on practical uptake, labeling the result “positive but underwhelming.” Ocular claims a win with eye drug data even as shares sink
• Negative Sentiment: Commentary points to potential regulatory and commercial hurdles (e.g., demonstrating meaningful advantage vs standard‑dose Eylea, pricing/reimbursement, and adoption), which could delay or limit upside even if FDA accepts a filing. Ocular Therapeutix eyes FDA filing with ph. 3 wet AMD win over Regeneron’s leading Eylea

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on OCUL shares. Jefferies Financial Group reiterated a “buy” rating on shares of Ocular Therapeutix in a report on Tuesday. Needham & Company LLC reissued a “buy” rating and set a $20.00 price objective on shares of Ocular Therapeutix in a report on Monday, December 8th. Citigroup restated an “outperform” rating on shares of Ocular Therapeutix in a report on Tuesday. Chardan Capital reissued a “buy” rating and issued a $21.00 price target on shares of Ocular Therapeutix in a research report on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ocular Therapeutix in a research report on Thursday, January 22nd. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $24.00.

About Ocular Therapeutix

Ocular Therapeutix, Inc is a biopharmaceutical company dedicated to the development of innovative therapies for diseases and conditions of the eye. Founded in 2011 and headquartered in Bedford, Massachusetts, the company focuses on sustained-release drug delivery platforms designed to address key unmet needs in ophthalmology. Its proprietary hydrogel-based inserts and sealants aim to improve patient compliance and outcomes by providing controlled release of active pharmaceutical ingredients directly to ocular tissues.

The company’s flagship product, DEXTENZA®, is a preservative-free, sustained-release dexamethasone intracanalicular insert approved by the U.S.